Evidence map›Paper›PMID 35797441›Full record

Trial reportCancer2022

Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention.

Louise A Koelmeyer, Katrina Gaitatzis, Mary S Dietrich, Chirag S Shah, John Boyages, Sarah A McLaughlin, Bret Taback, Deonni P Stolldorf, Elisabeth Elder, T Michael Hughes and 5 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 3 countries.

Louise A KoelmeyerAustralian Lymphoedema Education, Research, and Treatment (ALERT) Program, Faculty Medicine, Health & Human Sciences, Macquarie University, Sydney, New South Wales, Australia.ORCID 0000-0002-2736-2330
Katrina GaitatzisAustralian Lymphoedema Education, Research, and Treatment (ALERT) Program, Faculty Medicine, Health & Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Mary S DietrichVanderbilt University School of Nursing, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Chirag S ShahDepartment of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-9295-5554
John BoyagesAustralian Lymphoedema Education, Research, and Treatment (ALERT) Program, Faculty Medicine, Health & Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Sarah A McLaughlinMayo Clinic, Jacksonville, Florida, USA.
Bret TabackColumbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Deonni P StolldorfVanderbilt University School of Nursing, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Elisabeth ElderWestmead Breast Cancer Institute, Westmead, New South Wales, Australia.
T Michael HughesANU Clinical School at Sydney Adventist Hospital, Australian National University, Canberra, Australia.
James R FrenchWestmead Breast Cancer Institute, Westmead, New South Wales, Australia.
Nicholas NguiNorthern Surgical Oncology, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
Jeremy M HsuWestmead Breast Cancer Institute, Westmead, New South Wales, Australia.
Andrew MooreSoutheast Cancer Center, Cape Girardeau, Missouri, USA.
Sheila H RidnerVanderbilt University School of Nursing, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.ORCID 0000-0003-3847-7405
Vanderbilt University · USMacquarie University · AUThe University of Sydney · AUAustralian National University · AUBreast Center · CHCancer Institute of New South Wales · AUCleveland Clinic · USColumbia University · USJacksonville College · USSoutheast Missouri State University · USSydney Adventist Hospital · AU

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
NCATS NIH HHS UL1 TR000445
6 · The paper itself

Abstract

backgroundTo evaluate risk factors (treatment-related, comorbidities, and lifestyle) for breast cancer-related lymphedema (BCRL) within the context of a Prospective Surveillance and Early Intervention (PSEI) model of care for subclinical BCRL.

methodsThe parent randomized clinical trial assigned patients newly diagnosed with breast cancer to PSEI with either bioimpedance spectroscopy (BIS) or tape measurement (TM). Surgical, systemic and radiation treatments, comorbidities, and lifestyle factors were recorded. Detection of subclinical BCRL (change from baseline of either BIS L-Dex ≥6.5 or tape volume ≥ 5% and < 10%) triggered an intervention with compression therapy. Volume change from baseline ≥10% indicated progression to chronic lymphedema and need for complex decongestive physiotherapy. In this secondary analysis, multinomial logistic regressions including main and interaction effects of the study group and risk factors were used to test for factor associations with outcomes (no lymphedema, subclinical lymphedema, progression to chronic lymphedema after intervention, progression to chronic lymphedema without intervention). Post hoc tests of significant interaction effects were conducted using Bonferroni-corrected alphas of .008; otherwise, an alpha of .05 was used for statistical significance.

resultsThe sample (n = 918; TM = 457; BIS = 461) was female with a median age of 58.4 years. Factors associated with BCRL risk included axillary lymph node dissection (ALND) (p < .001), taxane-based chemotherapy (p < .001), regional nodal irradiation (RNI) (p ≤ .001), body mass index >30 (p = .002), and rurality (p = .037). Mastectomy, age, hypertension, diabetes, seroma, smoking, and air travel were not associated with BCRL risk.

conclusionsWithin the context of 3 years of PSEI for subclinical lymphedema, variables of ALND, taxane-based chemotherapy, RNI, body mass index >30, and rurality increased risk.

Indexed as

Breast Cancer LymphedemaBreast NeoplasmsLymphedemaAxillaFemaleHumansLymph Node ExcisionMastectomyMiddle AgedProspective StudiesRisk FactorsTaxoidsTaxoidsbioimpedance spectroscopybreast cancerinterventionlymphedemaprospective surveillance

Identifiers

PMID35797441
PMCPMC9542409
OpenAlexW4284682229

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.